The anti-SLAMF7 antibody elotuzumab mediates NK cell activation through both CD16-dependent and –independent mechanisms

Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM

(2016) A. Jakubowiak et al.   BLOOD

Cancer statistics, 2016

(2016) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Model-based pharmacokinetic analysis of elotuzumab in patients with relapsed/refractory multiple myeloma

(2016) Leonid Gibiansky et al.   JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS

Trans-inhibition of activation and proliferation signals by Fc receptors in mast cells and basophils

(2016) O. Malbec et al.   Science Signaling

Trans-inhibition of activation and proliferation signals by Fc receptors in mast cells and basophils

(2016) O. Malbec et al.   Science Signaling

Lenalidomide augments actin remodeling and lowers NK-cell activation thresholds

(2015) K. Lagrue et al.   BLOOD

CD38-Targeted Immunochemotherapy in Refractory Multiple Myeloma: A New Horizon

(2015) J. P. Laubach et al.   CLINICAL CANCER RESEARCH

Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma

(2015) Sagar Lonial et al.   NEW ENGLAND JOURNAL OF MEDICINE

Preclinical and clinical evaluation of elotuzumab, a SLAMF7-targeted humanized monoclonal antibody in development for multiple myeloma

(2015) Antonio Palumbo et al.   Expert Review of Hematology

The IMiDs targets IKZF-1/3 and IRF4 as novel negative regulators of NK cell-activating ligands expression in multiple myeloma

(2015) Cinzia Fionda et al.   Oncotarget

Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b–2 dose-escalation study

(2015) Paul G Richardson et al.   Lancet Haematology

Overexpression of KIR inhibitory ligands (HLA-I) determines that immunosurveillance of myeloma depends on diverse and strong NK cell licensing

(2015) María V. Martínez-Sánchez et al.   OncoImmunology

Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma

(2014) Y.-T. Tai et al.   BLOOD

Elotuzumab enhances natural killer cell activation and myeloma cell killing through interleukin-2 and TNF-α pathways

(2014) Balaji Balasa et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

EAT-2, a SAP-like adaptor, controls NK cell activation through phospholipase Cγ, Ca++, and Erk, leading to granule polarization

(2014) Luis-Alberto Pérez-Quintero et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Blockade of CD200 in the Presence or Absence of Antibody Effector Function: Implications for Anti-CD200 Therapy

(2014) A. Kretz-Rommel et al.   JOURNAL OF IMMUNOLOGY

Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC

(2013) Shauna M. Collins et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

CS1, a SLAM family receptor involved in immune regulation, is a therapeutic target in multiple myeloma

(2013) André Veillette et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Differential expression of natural killer cell activating receptors in blood versus bone marrow in patients with monoclonal gammopathy

(2013) Régis T. Costello et al.   IMMUNOLOGY

New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG)

(2013) E M Ocio et al.   LEUKEMIA

Combination Immune Therapies to Enhance Anti-Tumor Responses by NK Cells

(2013) Ashley Mentlik James et al.   Frontiers in Immunology

A phase 1 study of lucatumumab, a fully human anti-CD40 antagonist monoclonal antibody administered intravenously to patients with relapsed or refractory multiple myeloma

(2012) William Bensinger et al.   BRITISH JOURNAL OF HAEMATOLOGY

Elotuzumab in Combination With Lenalidomide and Low-Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma

(2012) Sagar Lonial et al.   JOURNAL OF CLINICAL ONCOLOGY

Latest advances and current challenges in the treatment of multiple myeloma

(2012) Anuj Mahindra et al.   Nature Reviews Clinical Oncology

SLAM Family Receptors and SAP Adaptors in Immunity

(2011) Jennifer L. Cannons et al.   Annual Review of Immunology

A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma

(2011) J. A. Zonder et al.   BLOOD

Multiple Myeloma

(2011) Antonio Palumbo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Therapy of B-cell malignancies by anti-HLA-DR humanized monoclonal antibody, IMMU-114, is mediated through hyperactivation of ERK and JNK MAP kinase signaling pathways

(2010) R. Stein et al.   BLOOD

Reduced immune effector cell NKG2D expression and increased levels of soluble NKG2D ligands in multiple myeloma may not be causally linked

(2009) Marie von Lilienfeld-Toal et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma

(2009) F. van Rhee et al.   MOLECULAR CANCER THERAPEUTICS

Influence of CRACC, a SLAM family receptor coupled to the adaptor EAT-2, on natural killer cell function

(2009) Mario-Ernesto Cruz-Munoz et al.   NATURE IMMUNOLOGY

ATM-ATR-dependent up-regulation of DNAM-1 and NKG2D ligands on multiple myeloma cells by therapeutic agents results in enhanced NK-cell susceptibility and is associated with a senescent phenotype

(2008) A. Soriani et al.   BLOOD

CS1, a Potential New Therapeutic Antibody Target for the Treatment of Multiple Myeloma

(2008) E. D. Hsi et al.   CLINICAL CANCER RESEARCH

Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu

(2007) Y.-T. Tai et al.   BLOOD